Skip to main content
. 2021 Nov 14;27(42):7350–7361. doi: 10.3748/wjg.v27.i42.7350

Table 3.

Associations between liver chemistries and outcomes

In-hospital mortality
In-hospital mortality or need for mechanical ventilation

Unadjusted analysis-HR (95%CI)
P value
Adjusted analysis1-HR (95%CI)
P value
Unadjusted analysis-HR (95%CI)
P value
Adjusted analysis1-HR (95%CI)
P value
AST
Normal Ref. Ref. Ref. Ref.
> 1 to ≤ 4 × ULN 1.29 (1.17-1.42) < 0.001 1.65 (1.47-1.85) < 0.001 1.29 (1.13-1.46) < 0.001 1.73 (1.47-2.04) < 0.001
> 4 to ≤ 10 × ULN 1.66 (1.38-1.99) < 0.001 1.69 (1.33-2.14) < 0.001 1.67 (1.27-2.20) < 0.001 2.09 (1.42-3.07) < 0.001
> 10 × ULN 3.50 (2.56-4.78) < 0.001 2.64 (1.73-4.04) < 0.001 3.89 (2.48-6.10) < 0.001 3.38 (1.78-6.40) < 0.001
ALT
Normal Ref. Ref. Ref. Ref.
> 1 to ≤ 4 × ULN 0.84 (0.77-0.91) < 0.001 1.21 (1.09-1.34) < 0.001 0.72 (0.63-0.81) < 0.001 1.20 (1.02-1.40) 0.02
> 4 to ≤ 10 × ULN 0.88 (0.71-1.09) 0.24 1.22 (0.93-1.61) 0.15 0.79 (0.57-1.09) 0.15 1.40 (0.87-2.26) 0.16
> 10 × ULN 1.71 (1.20-2.45) 0.003 1.34 (0.81-2.22) 0.26 1.42 (0.80-2.51) 0.23 1.36 (0.58-3.19) 0.48
Alkaline phosphatase
Normal Ref. Ref. Ref. Ref.
Elevated 1.27 (1.14-1.43) < 0.001 1.29 (1.12-1.48) < 0.001 1.19 (1.01-1.42) 0.04 1.39 (1.12-1.72) 0.003
Bilirubin
Normal Ref. Ref. Ref. Ref.
Elevated 1.55 (1.32-1.82) < 0.001 1.12 (0.92-1.37) 0.27 1.69 (1.34-2.13) < 0.001 0.96 (0.71-1.30) 0.79
AST:ALT ratio
≤ 1 Ref. Ref. Ref. Ref.
> 1 2.08 (1.82-2.37) < 0.001 1.72 (1.46-2.02) < 0.001 2.61 (2.13-3.19) < 0.001 1.84 (1.41-2.40) < 0.001
Pattern of liver injury2
Normal or non-severe Ref. Ref. Ref. Ref.
Hepatocellular 0.93 (0.80-1.09) 0.39 0.90 (0.74-1.11) 0.33 0.84 (0.66-1.07) 0.15 1.18 (0.85-1.65) 0.33
Mixed 1.14 (0.74-1.75) 0.56 1.06 (0.65-1.73) 0.82 1.00 (0.52-1.93) 0.99 1.02 (0.44-2.37) 0.96
Cholestatic 1.17 (0.85-1.61) 0.33 1.57 (1.07-2.28) 0.02 1.25 (0.81-1.93) 0.31 2.05 (1.17-3.58) 0.01
1

Adjusted for age (time-varying), sex (time-varying), race (time-varying), ethnicity, and comorbidities (obesity, hypertension, diabetes, coronary artery disease, chronic kidney disease, end-stage renal disease, chronic obstructive pulmonary disease, heart failure, and cancer).

2

Defined as: Normal or non-severe [alanine aminotransferase (ALT) ≤ 3 × ULN and alkaline phosphatase ≤ 2 × upper limit of normal (ULN)], hepatocellular (ALT > 3 × ULN and alkaline phosphatase ≤ 2 × ULN), mixed (ALT > 3 × ULN and alkaline phosphatase > 2 × ULN), and cholestatic (ALT ≤ 3 × ULN and alkaline phosphatase > 2 × ULN).

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CI: Confidence interval; HR: Hazard ratio; ULN: Upper limit of normal.